A Phase 1 study reported durability differences for an H5N1 self-amplifying mRNA vaccine, with an eight-week dosing interval producing stronger and longer-lasting antibody responses than a four-week schedule. The candidate, ARCT-2304, was tested using interval-based regimens aimed at optimizing immune kinetics for pandemic-relevant protection. The report adds to the ongoing race to define vaccine schedules that balance logistics with measurable immunogenicity duration. For developers, the signal is practical: dosing interval selection may materially change the time window of protection rather than simply the magnitude of response. The findings are early but clinically relevant for next-step trial design, especially where manufacturing and deployment constraints make spacing decisions difficult to revise later.